Mesoblast (ASX:MSB) reported Thursday a fiscal first-half loss of $0.042 per diluted share, compared with a loss of $0.0372 a year earlier.
Analysts surveyed by Visible Alpha expected a loss of $0.05.
Revenue for the six months ended Dec. 31, 2024, was $3.2 million, down from $3.4 million a year earlier. Analysts surveyed by Visible Alpha expected $3 million.
The board did not declare a dividend and "do not anticipate paying dividends in the foreseeable future," per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.